The first drugs against Alzheimer's disease that are intended to slow down the progression of the condition will soon be authorized in Germany. On November 14, 2024, the EMA granted approval for ...

The members of the Amyloid imaging to prevent Alzheimer's disease (AMYPAD) have announced the publication of a perspective ...

US clinical stage biotech Alector saw its shares tumble 35% to $2.57 by close of trading yesterday, as it announced ...

More astrocytes were distributed around the amyloid plaques in the brain of the patient with genetic AD. Figure 4 PET sections through the basal ganglia (left) and cerebral cortex (right) of the brain ...

Alector's AL002 fails in Phase 2 Alzheimer's trial, halting extension study; focus shifts to other programs as workforce is ...

In Madrid, Molina-Henry attributed most of these screen failures to volunteers having negative AD blood biomarker tests. The trial aimed to enroll cognitively normal people with 20 to 40 centiloids of ...

aWaisman Center, University of Wisconsin-Madison, Madison, WI, USA bAlzheimer's Disease Research Center, University of Wisconsin-Madison, Madison, WI, USA cSchool of Human Ecology, University of ...

Alector, Inc. (Nasdaq: ALEC), a clinical-stage biotechnology company pioneering novel, genetically validated therapies for ...